Deciphering colorectal cancer genetics through multi-omic analysis of 100,204 cases and 154,587 controls of European and east Asian ancestries
- PMID: 36539618
- PMCID: PMC10094749
- DOI: 10.1038/s41588-022-01222-9
Deciphering colorectal cancer genetics through multi-omic analysis of 100,204 cases and 154,587 controls of European and east Asian ancestries
Erratum in
-
Author Correction: Deciphering colorectal cancer genetics through multi-omic analysis of 100,204 cases and 154,587 controls of European and east Asian ancestries.Nat Genet. 2023 Mar;55(3):519-520. doi: 10.1038/s41588-023-01334-w. Nat Genet. 2023. PMID: 36782065 No abstract available.
Abstract
Colorectal cancer (CRC) is a leading cause of mortality worldwide. We conducted a genome-wide association study meta-analysis of 100,204 CRC cases and 154,587 controls of European and east Asian ancestry, identifying 205 independent risk associations, of which 50 were unreported. We performed integrative genomic, transcriptomic and methylomic analyses across large bowel mucosa and other tissues. Transcriptome- and methylome-wide association studies revealed an additional 53 risk associations. We identified 155 high-confidence effector genes functionally linked to CRC risk, many of which had no previously established role in CRC. These have multiple different functions and specifically indicate that variation in normal colorectal homeostasis, proliferation, cell adhesion, migration, immunity and microbial interactions determines CRC risk. Crosstissue analyses indicated that over a third of effector genes most probably act outside the colonic mucosa. Our findings provide insights into colorectal oncogenesis and highlight potential targets across tissues for new CRC treatment and chemoprevention strategies.
© 2022. The Author(s), under exclusive licence to Springer Nature America, Inc.
Conflict of interest statement
Competing interests
AC is consultant to Bayer Pharma AG, Boehringer Ingelheim, and Pfizer Inc. for work unrelated to this manuscript; AS is an employee at Insitro, incl. consulting fees from BMS; HH is SAB for Invitae Genetics, Promega, and Genome Medical. Stock/Stock options for Genome Medical and GI OnDemand; JK is a consultant for Guardant Health; NP is a collaborator for Thrive and Exact, PGDx, CAGE, NeoPhore, Vidium, ManaTbio, and receives royalties for licensed technologies according to JHU rules; RKP collaborates with Eli Lilly, AbbVie, Allergan, Verily, and Alimentiv, which include consulting fees (outside of the submitted work); SAB has financial interest in Adaptive Biotechnologies; SBG is co-founder, Brogent International LLC; TSM receives research and honoraria from Merck Serono; ZKS’s immediate family member serves as a consultant in Ophthalmology for Alcon, Adverum, Gyroscope Therapeutics Limited, Neurogene, and RegenexBio (outside the submitted work). VM has research projects and owns stocks of Aniling. The remaining authors declare no competing interests.
Figures



References
-
- Sung H, Ferlay J, Siegel R, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021. - PubMed
-
- Zhu Z, Zhang F, Hu H, et al. Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets. Nat Genet. 2016;48(5):481–487. - PubMed
Methods-onlyreferences
-
- Johns LE, Houlston RS. A systematic review and meta-analysis of familial colorectal cancer risk. Am J Gastroenterol. 2001;96(10):2992–3003. - PubMed
Publication types
MeSH terms
Grants and funding
- MC_PC_U127527198/MRC_/Medical Research Council/United Kingdom
- P30 CA015704/CA/NCI NIH HHS/United States
- U01 CA137088/CA/NCI NIH HHS/United States
- U01 CA164930/CA/NCI NIH HHS/United States
- MR/K026992/1/MRC_/Medical Research Council/United Kingdom
- 18927/CRUK_/Cancer Research UK/United Kingdom
- G0700704/MRC_/Medical Research Council/United Kingdom
- U01 CA074783/CA/NCI NIH HHS/United States
- U19 CA148107/CA/NCI NIH HHS/United States
- MC_UU_00007/10/MRC_/Medical Research Council/United Kingdom
- MC_UU_00007/1/MRC_/Medical Research Council/United Kingdom
- 22804/CRUK_/Cancer Research UK/United Kingdom
- R01 CA059045/CA/NCI NIH HHS/United States
- R01 CA197350/CA/NCI NIH HHS/United States
- R01 CA188214/CA/NCI NIH HHS/United States
- P30 ES010126/ES/NIEHS NIH HHS/United States
- R35 CA197442/CA/NCI NIH HHS/United States
- MR/P001106/1/MRC_/Medical Research Council/United Kingdom
- R37 CA227130/CA/NCI NIH HHS/United States
- 29186/CRUK_/Cancer Research UK/United Kingdom
- C6199/A16459/CRUK_/Cancer Research UK/United Kingdom
- R01 CA206279/CA/NCI NIH HHS/United States
- 12076/CRUK_/Cancer Research UK/United Kingdom
- S10 OD028685/OD/NIH HHS/United States
- R37 CA070867/CA/NCI NIH HHS/United States
- R01 CA244588/CA/NCI NIH HHS/United States
- HHSN268201200008C/HL/NHLBI NIH HHS/United States
- MC_U127527198/MRC_/Medical Research Council/United Kingdom
- 19167/CRUK_/Cancer Research UK/United Kingdom
- U01 CA167551/CA/NCI NIH HHS/United States
- C6199/A27327/CRUK_/Cancer Research UK/United Kingdom
- P30 CA008748/CA/NCI NIH HHS/United States
- R01 CA269589/CA/NCI NIH HHS/United States
- C1298/A25514/CRUK_/Cancer Research UK/United Kingdom
- P30 CA014089/CA/NCI NIH HHS/United States
- R01 CA148667/CA/NCI NIH HHS/United States
- R01 CA081488/CA/NCI NIH HHS/United States
- MR/K018647/1/MRC_/Medical Research Council/United Kingdom
- R01 CA124558/CA/NCI NIH HHS/United States
- R01 CA201407/CA/NCI NIH HHS/United States
- P30 CA068485/CA/NCI NIH HHS/United States
- T32 ES013678/ES/NIEHS NIH HHS/United States
- P30 CA016058/CA/NCI NIH HHS/United States
- C348/A12076/CRUK_/Cancer Research UK/United Kingdom
- 27327/CRUK_/Cancer Research UK/United Kingdom
- P01 CA196569/CA/NCI NIH HHS/United States
- UM1 CA182910/CA/NCI NIH HHS/United States
- R01 CA158473/CA/NCI NIH HHS/United States
- HHSN268201200008I/HL/NHLBI NIH HHS/United States
- 25514/CRUK_/Cancer Research UK/United Kingdom
- 001/WHO_/World Health Organization/International
LinkOut - more resources
Full Text Sources
Medical